- Emmy-winning and Golden Globe-nominated actress Uzo Aduba will run the 119th Boston Marathon® on Monday, April 20 as a member of the Dana-Farber Marathon Challenge team to support cancer research at Dana-Farber Cancer Institute.
- According to a new study led by Dana-Farber researchers, patients with metastatic colorectal cancer who had high levels of vitamin D in their bloodstream prior to treatment with chemotherapy and targeted drugs, survived longer, on average, than patients with lower levels of the vitamin.
Tags: BasicResearch, ColonCancer, Nutrition
- Dana-Farber researchers report women with small, HER2-positive breast tumors who received a combination of lower-intensity chemotherapy and a targeted drug following surgery were highly unlikely to have the cancer recur within three years.
Tags: BreastCancer, TargetedTherapy
- In a clinical trial involving women with triple-negative breast cancer, patients who received the drugs carboplatin and/or bevacizumab in combination with standard chemotherapy prior to surgery were more likely to have their tumors disappear entirely from the breast, according to data presented by investigators during the 2014 San Antonio Breast Cancer Symposium.
- Adding a PI3K inhibitor to hormonal therapy for metastatic breast cancer may help overcome resistance to the hormonal therapy and delay disease progression, according to investigators from Dana-Farber Cancer Institute.
- Common variations in four genes related to brain inflammation or cells' response to damage from oxidation may contribute to the problems with memory, learning and other cognitive functions seen in children treated for acute lymphoblastic leukemia (ALL), according to research presented at the annual American Society of Hematology annual meeting in San Francisco.
Tags: ChildhoodCancer, Survivorship, Leukemia
- A study led by Dana-Farber investigators found that a phase 1 trial of an immune checkpoint blocker found clinical benefit in nearly half of blood cancer patients who had relapsed following allogeneic stem cell transplantation.
Tags: MultipleMyeloma, Leukemia, Immunotherapy
- Small cell lung cancer – a disease for which no new drugs have been approved for many years – has shown itself vulnerable to an agent that disables part of tumor cells’ basic survival machinery, researchers at Dana-Farber Cancer Institute and the Massachusetts Institute of Technology reported.
Tags: Genomics, LungCancer
- Findings by Dana-Farber scientists and others show the disarray in the on-off mechanism – known as methylation – is one of the defining characteristics of cancer and helps tumors adapt to changing circumstances.
Tags: BasicResearch, Genomics
Showing 11-20 of 571 items